非酒精性脂肪性肝病的病理改变及相关分子机制

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)是一种以脂肪堆积为特征的慢性肝病,其组织学表现存在一定异质性。NAFLD的病理表现包括肝细胞脂肪变性、肝细胞气球样变、炎症和纤维化、肝硬化。近年来随着分子生物学、遗传学和免疫学多学科技术发展,研究人员从分子水平对NAFLD不同病理过程进行了探索,不断为临床医生和科研人员提供更好的诊断评估方法、发病机制、形态学特征和疾病进展的预测标志物。

关键词: 非酒精性脂肪性肝病, 分子机制, 肝细胞脂肪变性, 肝细胞气球样变, 炎症, 纤维化

高静雯, 刘晓琳, 朱锦舟, 许春芳. 非酒精性脂肪性肝病的病理改变及相关分子机制[J]. 肝脏, 2022, 27(2): 144-147.

[1] Yang X, Sun D, Xiang H, et al. Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD. Hepatology,2021,74:1319-1338.
[2] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology,2016,64:73-84.
[3] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol,2020,73:202-209.
[4] Poisson J, Lemoinne S, Boulanger C, et al. Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J Hepatol,2017,66:212-227.
[5] Dixon LJ, Barnes M, Tang H, et al. Kupffer cells in the liver. Compr Physiol,2013,3:785-797.
[6] Marrone G, Shah VH, Gracia-Sancho J Sinusoidal communication in liver fibrosis and regeneration. J Hepatol,2016,65:608-617.
[7] Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology,2011,54:344-553.
[8] Ma N, Wang YK, Xu S, et al. PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling. Nat Commun,2021,12:3059.
[9] Chalasani N, Wilson L, Kleiner DE, et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol,2008,48:829-834.
[10] Cataldo I, Sarcognato S, Sacchi D, et al. Pathology of non-alcoholic fatty liver disease. Pathologica,2021,113:194-202.
[11] Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest,2005,115:1343-1351.
[12] Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci,2018,75:3313-3327.
[13] Rada P, González-Rodríguez Á, García-Monzón C, et al. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell Death Dis,2020,11:802.
[14] Nguyen TTP, Kim DY, Lee YG, et al. SREBP-1c impairs ULK1 sulfhydration-mediated autophagic flux to promote hepatic steatosis in high-fat-diet-fed mice. Mol Cell,2021,81:1-13.
[15] Fabbrini E, Mohammed BS, Magkos F, et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology,2008,134:424-431.
[16] 邵幼林, 范建高. 非酒精性脂肪性肝病患者肝脏脂肪的来源与去路. 国际消化病杂志,2019,39:316-320.
[17] Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology,2007,46:1081-1090.
[18] Zhang MH, Li J, Zhu XY, et al. Physalin B ameliorates nonalcoholic steatohepatitis by stimulating autophagy and NRF2 activation mediated improvement in oxidative stress. Free Radic Biol Med,2021,164:1-12.
[19] Chen L, Wu N, Kennedy L, et al. Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes. Hepatology,2021,74:1845-1863.
[20] Afonso MB, Rodrigues PM, Mateus-Pinheiro M, et al. RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. Gut,2021,70(12):2359-2372.
[21] Tosello-Trampont AC, Landes SG, Nguyen V, et al. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J Biol Chem,2012,287:40161-40172.
[22] Baeck C, Wehr A, Karlmark KR, et al. Pharmacological inhibition of the chemokine CCL2 ((MCP-1)) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut,2012,61:416-426.
[23] Mridha AR, Wree A, Robertson AAB, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol,2017,66:1037-1046.
[24] Kremer M, Hines IN, Milton RJ, et al. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. Hepatology,2006,44:216-227.
[25] Ghazarian M, Revelo XS, Nøhr MK, et al. Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome. Sci Immunol,2017,2((10)):eaai7616.
[26] Winer DA, Winer S, Shen L, et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med,2011,17:610-617.
[27] Lackner C, Gogg-Kamerer M, Zatloukal K, et al. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol,2008,48:821-828.
[28] Guy CD, Suzuki A, Burchette JL, et al. Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. Hum Pathol,2012,43:790-800.
[29] Schwabe RF, Tabas I, Pajvani UB Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology,2020,158:1913-1928.
[30] Chen L, Wu N, Kennedy L, et al. Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes. Hepatology,2021,74:1845-1863.
[31] Torbenson M, Chen YY, Brunt E, et al. Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol,2006,30:508-513.
[32] Tandra S, Yeh MM, Brunt EM, et al. Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol,2011,55:654-659.
[33] Jia M, Zhang H, Qin Q, et al. Ferroptosis as a new therapeutic opportunity for nonviral liver disease. Eur J Pharmacol,2021,908:174319.
[34] Li X, Wang TX, Huang X, et al. Targeting ferroptosis alleviates methionine-choline deficient ((MCD))-diet induced NASH by suppressing liver lipotoxicity. Liver Int,2020,40:1378-1394.
[35] Britton L, Jaskowski LA, Bridle K, et al. Ferroportin Expression in Adipocytes Does Not Contribute to Iron Homeostasis or Metabolic Responses to a High Calorie Diet. Cell Mol Gastroenterol Hepatol,2018,5:319-331.

非酒精性脂肪性肝病的病理改变及相关分子机制

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨永勤, 王晓君, 冯巩, 李嵘, 刘小瑜, 孙雪梅, 贺娜. 基于Nomogram的NAFLD进展性纤维化预测模型研究[J]. 肝脏, 2022, 27(2): 160-163.
[2]	肖珊珊, 杨巧红, 李建婷. 低水平HBsAg慢性乙型肝炎患者炎症分级及纤维化分期观察[J]. 肝脏, 2022, 27(2): 225-227.
[3]	唐慧昕, 张译之, 陈煜. 干细胞来源外泌体在急性肝衰竭炎症驱动中的应用价值[J]. 肝脏, 2022, 27(1): 8-11.
[4]	黎妮, 黄裕林, 马世河. 血Tim-3联合γ-GT/胆碱酯酶比值在转氨酶正常或轻度升高慢性乙型肝炎患者中的临床价值[J]. 肝脏, 2022, 27(1): 42-46.
[5]	肖倩倩, 王梦雨, 范建高. 非酒精性脂肪性肝病综合诊疗模式[J]. 肝脏, 2021, 26(9): 951-952.
[6]	张警予, 赵红, 谢雯. 氨基酸在慢加急性肝衰竭病理生理机制中的作用[J]. 肝脏, 2021, 26(9): 958-960.
[7]	李静, 雷晓红, 茅益民. NFATc4在NASH领域的研究进展[J]. 肝脏, 2021, 26(9): 960-961.
[8]	徐芳, 张海泉, 赵佳强. 低水平HBsAg患者纤维化分期特征及其与血小板的相关性分析[J]. 肝脏, 2021, 26(9): 977-979.
[9]	焦芳芳, 张伟, 武云珍. 急重症胰腺炎合并肝损伤患者IL-10、TGFβ及其mRNA水平与肝功能指标的相关性[J]. 肝脏, 2021, 26(9): 1027-1030.
[10]	王泳而, 汪艳. 果糖代谢与非酒精性脂肪性肝病的机制关系[J]. 肝脏, 2021, 26(8): 838-839.
[11]	徐贤军, 陆伦根. 丙型肝炎病毒根除后肝纤维化逆转基础和临床研究[J]. 肝脏, 2021, 26(8): 840-842.
[12]	李兰亚, 伍广, 屠涛, 张丽. 慢性乙型肝炎患者外周血NK细胞水平与肝纤维化的相关性[J]. 肝脏, 2021, 26(8): 879-882.
[13]	韦玉亚, 朱婷, 唐文静, 方静. 实时超声剪切波成像技术联合血清学指标、APRI指数评估慢性乙型肝炎纤维化程度的价值[J]. 肝脏, 2021, 26(8): 883-886.
[14]	赵宏伟, 祝佳, 张国良, 白雪峰, 韩飞, 林光耀. 原发性胆汁性胆管炎患者磁共振检查肝脏表现特点分析[J]. 肝脏, 2021, 26(8): 903-906.
[15]	李小祥, 顾小丹, 许卫东. 血浆促酰基化蛋白与肥胖型非酒精性脂肪性肝病的相关性[J]. 肝脏, 2021, 26(8): 913-916.